Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and...

Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+...

Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer ( Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain )

ESMO 2021: PARPi data and their role in mono/combination therapies

Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong

ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )

ESMO 2021: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve...

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer